The drug industry is shattering capital-raising records in 2020, as investors funnel money into pharmaceutical and biotech companies. Business Insider spoke with top venture capitalists about why this is happening and how they plan to take advantage. Several VCs said they are advising biotechs that are now considering going public earlier than expected because of the booming public market. Biotech is still a risky gambit, VCs say, but money has flowed into the space as other industries, clobbered by the pandemic, appear shakier than usual. For more stories like this, sign up here for our healthcare newsletter, Dispensed.